Lung cancer treatment has been fundamentally transformed by the rise of Next-Generation Sequencing (NGS). As of March 31, 2026, we no longer treat "lung cancer" as a single disease. Instead, we use NGS to decode the tumor's unique genetic fingerprint, identifying mutations like EGFR, ALK, ROS1, and KRAS with surgical precision.

At Onco Medicine, we are providing the companion diagnostics and specialized medications necessitated by these findings. By sequencing billions of base pairs in a single run, NGS allows oncologists to select the "Best Fit" medication for each patient on Day 1 of treatment.

Why NGS is the Gold Standard

• Multi-Targeted Analysis: Screening for hundreds of actionable mutations simultaneously rather than testing them one-by-one.
• Detecting Rare Variants: Identifying rare "fusions" (like RET or NTRK) that standard tests often miss.
• Real-Time Monitoring: Using "Liquid NGS" (blood tests) to track how the tumor genomic profile changes during treatment.
• Personalized Dosaging: Using genetic data to predict how a patient will metabolize specific immunotherapy agents.

Personalized treatment isn't a goal—it is our current reality. By starting with a genomic map, we ensure that every pill, infusion, and clinical decision is backed by the biology of the patient. Onco Medicine is your trusted bridge to this advanced diagnostic world.